Open your refrigerator, your laundry cabinet, and the fuel tank of a flex-fuel car, and you have probably touched Novonesis without ever seeing its name. The Danish company does not sell to consumers. It sells to the companies that sell to consumers - the dairies, bakeries, detergent makers, feed mills, biofuel plants and supplement brands that need a specific biological trick performed at scale. That trick is almost always the same: get a microbe or an enzyme to do a job that chemistry, heat or brute force used to do more expensively.
Novonesis is barely two years old as a name. It was created in January 2024, when two century-spanning Danish biotech firms - the enzyme specialist Novozymes and the cultures-and-probiotics house Chr. Hansen - completed a merger. The combined group employs roughly 11,000 people and books about EUR 3.7 billion in annual sales. In the narrow, unglamorous world of industrial biosolutions, it is the largest company there is.
Selling the invisible ingredient
Strip away the language of "biosolutions" and the business is concrete. An enzyme is a protein that speeds up a specific reaction - breaking a starch into sugar, loosening a stain, cutting gluten into smaller pieces. A microbial culture is a living organism selected to do something useful, like turning milk into yogurt or fixing nitrogen at a plant's roots. Novonesis discovers these, improves them, manufactures them by fermentation, and sells them by the drum to manufacturers who blend them into their own products.
The appeal to customers is usually some mix of three things: a product that works better, a process that uses less energy or water, or a chemical that can be removed from the recipe. Enzymes are a large part of why laundry detergent now cleans effectively in cold water - a change that quietly cut household energy use across the world.
Six businesses, one toolkit
The company organizes itself around two broad divisions - Food & Health Biosolutions and Planetary Health Biosolutions - but the customer-facing work spans six application areas. The underlying toolkit, a library of strains and enzymes plus the know-how to apply them, is shared across all of them.
One product line illustrates the strategy neatly. Novonesis says its BB-12 strain is the world's most documented Bifidobacterium probiotic. The claim is really about data: decades of studies, published and cited, make it easy for a supplement or infant-formula company to justify choosing it. Own the strain, own the evidence, own the shelf.
A near-monopoly on a niche
The reason Novonesis matters more than its modest brand recognition suggests is concentration. Analysts put its share of the industrial enzyme and microbial solutions markets at around half. In categories this specialized, that kind of position is built slowly - through strain libraries collected over decades, patents stacked one on another, and application engineers who know a customer's factory better than the customer's own staff.
Everyone else ~50%
"Everyone else" is not nothing. The competitive set includes IFF, dsm-firmenich, Kerry Group and ADM - large, capable ingredient companies. But no single rival matches Novonesis across both enzymes and cultures at the same time, which is precisely the gap the Novozymes-Chr. Hansen merger was designed to close.
Ingredients, not brands
Novonesis is a B2B supplier, and that shapes everything. Revenue is recurring - customers who reformulate a detergent or a feed additive around a particular enzyme do not switch casually. Margins are protected by patents and by the sheer difficulty of reproducing a specific strain's performance. And growth tends to be steady rather than explosive: in 2024, its first full year, the group reported 8% organic pro forma sales growth, and Q1 2026 showed 7% organic growth with an adjusted EBITDA margin near 38%.
The trade-off is anonymity. A company that sells the ferment behind your cheese and the enzyme behind your fuel will never have the name recognition of the brands on the shelf. For an ingredient supplier, that is the job, not a flaw.
RootsTwo long histories, one company
The name is new; the science is not. Chr. Hansen dates to 1874, when Christian D. A. Hansen began producing standardized rennet for cheesemakers. Novozymes was carved out as a standalone enzyme business in 2000, itself the descendant of decades of fermentation work at Novo Nordisk. Merging them created a company whose competitive advantage is measured in generations of accumulated biological data.
Run by a chemist, sold as a mission
Novonesis is led by CEO Ester Baiget, who steered the merger and its integration. She describes a leadership style built on humility, transparency and a focus on durable growth rather than quarterly heroics - a fitting stance for a business whose product cycles are measured in strain generations. Internally, the company frames its work around the argument that biology can quietly displace energy- and chemical-intensive industrial processes.
Whether "biosolutions" becomes a category the wider world recognizes, or stays a term of art among procurement managers, Novonesis has already made its bet. It has the strains, the patents and, for now, roughly half the market. The rest of us just keep washing clothes in cold water and never asking why.